RIM ponders hardware sale
By Bloomberg News
Published: Tuesday, January 22, 2013, 12:01 a.m.
Updated: Tuesday, February 19, 2013
Research In Motion Ltd. jumped to to its highest level since late 2011 after its chief executive officer said the BlackBerry maker is considering strategic options, including a sale of its hardware production unit.
Possibilities include “the sale of hardware production as well as licensing of our software,” CEO Thorsten Heins was reported as saying in an interview with German newspaper Die Welt. Nick Manning, a spokesman for the Waterloo, Ontario-based company, said those options are examples that Heins cited among the possibilities under consideration in a strategic review.
The company hired JPMorgan Chase & Co. and RBC Capital Markets in May to help it evaluate options. While Heins hasn't ruled out a sale of the company, he has said RIM's focus is on exploring strategic partnerships or software licensing deals. On Jan. 30, RIM will debut the BlackBerry 10 devices, which the company is counting on to reverse a sales slide and help it win back market share lost to Apple Inc.'s iPhone and handsets that run Google Inc.'s Android software.
RIM closed up 15 percent to $18.23 in Toronto after climbing as high as $18.60 earlier in the day, the highest since Dec. 1, 2011.
The stock has more than doubled since September on growing optimism for BlackBerry 10's prospects. RIM didn't trade on Monday in New York because of the Martin Luther King Jr. holiday.
The strategic review continues “but there is no reason for us to rush to decide,” Heins was quoted as saying by Die Welt. “First and foremost, it's important to bring BlackBerry 10 successfully to market.”
- Highmark to extend self-insurance plans to small businesses
- United makes MileagePlus status harder to achieve
- FedEx 4Q profit drops as economic growth is weak
- SEC investigation to continue into ‘suspicious’ acquisition of Heinz stock option
- ExOne, furnace maker agree to jointly market products
- Fed says it will continue $85B in bond purchases
- Pending FDA approval, trials to begin on ALung’s artificial lung
- More choose to buy into jobs
- Apple details requests for customers’ data
- Markets anxious in wait for Fed
- Merck, Pfizer sue to block proposed version of AzaSite
You must be signed in to add comments
To comment, click the Sign in or sign up at the very top of this page.
Subscribe today! Click here for our subscription offers.